NKTR
Income statement / Annual
Last year (2023), Nektar Therapeutics's total revenue was $90.12 M,
a decrease of 2.10% from the previous year.
In 2023, Nektar Therapeutics's net income was -$276.06 M.
See Nektar Therapeutics,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$90.12 M
|
$92.06 M
|
$101.91 M
|
$152.92 M
|
$114.62 M
|
$1.19 B
|
$307.71 M
|
$165.44 M
|
$230.78 M
|
$200.71 M
|
| Cost of Revenue |
$36.64 M |
$21.64 M |
$24.90 M |
$19.48 M |
$21.37 M |
$24.41 M |
$30.55 M |
$30.22 M |
$34.10 M |
$28.53 M |
| Gross Profit |
$53.48 M |
$70.42 M |
$77.01 M |
$133.44 M |
$93.24 M |
$1.17 B |
$277.16 M |
$135.22 M |
$196.68 M |
$172.17 M |
| Gross Profit Ratio |
0.59 |
0.76 |
0.76 |
0.87 |
0.81 |
0.98 |
0.9 |
0.82 |
0.85 |
0.86 |
| Research and Development
Expenses |
$114.16 M
|
$218.32 M
|
$400.27 M
|
$408.68 M
|
$434.57 M
|
$399.54 M
|
$268.46 M
|
$203.80 M
|
$182.79 M
|
$147.73 M
|
| General & Administrative
Expenses |
$77.42 M
|
$92.33 M
|
$122.84 M
|
$104.68 M
|
$98.71 M
|
$81.44 M
|
$52.36 M
|
$44.28 M
|
$43.27 M
|
$40.93 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$77.42 M
|
$92.33 M
|
$122.84 M
|
$104.68 M
|
$98.71 M
|
$81.44 M
|
$52.36 M
|
$44.28 M
|
$43.27 M
|
$40.93 M
|
| Other Expenses |
$0.00 |
-$116,000.00 |
-$24.41 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$190.90 M |
$310.66 M |
$523.11 M |
$513.36 M |
$533.28 M |
$480.98 M |
$320.83 M |
$248.08 M |
$226.05 M |
$188.66 M |
| Cost And Expenses |
$227.55 M |
$332.29 M |
$548.01 M |
$532.84 M |
$554.65 M |
$505.39 M |
$351.37 M |
$278.29 M |
$260.16 M |
$217.19 M |
| Interest Income |
$19.01 M |
$6.67 M |
$2.57 M |
$18.28 M |
$46.34 M |
$37.57 M |
$4.52 M |
$2.39 M |
$1.68 M |
$814,000.00 |
| Interest Expense |
$25.33 M |
$28.91 M |
$47.31 M |
$37.12 M |
$46.35 M |
$42.78 M |
$40.95 M |
$42.18 M |
$38.90 M |
$38.76 M |
| Depreciation &
Amortization |
$7.82 M
|
$12.20 M
|
$13.00 M
|
$12.50 M
|
$11.00 M
|
$8.80 M
|
$12.60 M
|
$13.20 M
|
$12.86 M
|
$12.93 M
|
| EBITDA |
-$243.11 M
|
-$323.87 M
|
-$462.97 M
|
-$394.33 M
|
-$382.70 M
|
$734.30 M
|
-$42.52 M
|
-$97.27 M
|
-$29.37 M
|
-$2.74 M
|
| EBITDA Ratio |
-2.7 |
-2.4 |
-4.45 |
-2.27 |
-3.32 |
0.62 |
-0.08 |
-0.57 |
-0.06 |
-0.01 |
| Operating Income Ratio
|
-1.52
|
-2.61
|
-4.38
|
-2.48
|
-3.84
|
0.58
|
-0.19
|
-0.68
|
-0.13
|
-0.08
|
| Total Other
Income/Expenses Net |
-$138.83 M
|
-$124.75 M
|
-$77.18 M
|
-$64.03 M
|
-$19,000.00
|
-$5.21 M
|
-$36.43 M
|
-$39.79 M
|
-$51.30 M
|
-$37.94 M
|
| Income Before Tax |
-$276.26 M |
-$364.98 M |
-$523.28 M |
-$443.95 M |
-$440.05 M |
$682.73 M |
-$96.08 M |
-$152.65 M |
-$80.67 M |
-$54.43 M |
| Income Before Tax Ratio
|
-3.07
|
-3.96
|
-5.13
|
-2.9
|
-3.84
|
0.57
|
-0.31
|
-0.92
|
-0.35
|
-0.27
|
| Income Tax Expense |
-$200,000.00 |
$3.22 M |
$557,000.00 |
$493,000.00 |
$613,000.00 |
$1.41 M |
$616,000.00 |
$876,000.00 |
$506,000.00 |
-$512,000.00 |
| Net Income |
-$276.06 M |
-$368.20 M |
-$523.84 M |
-$444.44 M |
-$440.67 M |
$681.31 M |
-$96.69 M |
-$153.52 M |
-$81.18 M |
-$53.92 M |
| Net Income Ratio |
-3.06 |
-4 |
-5.14 |
-2.91 |
-3.84 |
0.57 |
-0.31 |
-0.93 |
-0.35 |
-0.27 |
| EPS |
-1.45 |
-1.97 |
-2.86 |
-2.49 |
-2.52 |
3.78 |
-0.62 |
-1.1 |
-0.61 |
-0.42 |
| EPS Diluted |
-1.45 |
-1.97 |
-2.86 |
-2.49 |
-2.52 |
3.78 |
-0.62 |
-1.1 |
-0.61 |
-0.42 |
| Weighted Average Shares
Out |
$190.00 M
|
$187.14 M
|
$183.30 M
|
$178.58 M
|
$174.99 M
|
$180.12 M
|
$155.95 M
|
$139.57 M
|
$132.46 M
|
$126.87 M
|
| Weighted Average Shares
Out Diluted |
$190.00 M
|
$187.14 M
|
$183.30 M
|
$178.58 M
|
$174.99 M
|
$180.12 M
|
$155.95 M
|
$139.60 M
|
$132.46 M
|
$126.87 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
